The biopharmaceuticals industry has undergone a number of revolutions in the past decade, not least the variety of ‘omics’ that focus on high throughput technologies to identify new product targets and can rapidly characterise those targets at small scale. However, it has been widely recognised that the technology used in the manufacturing of these in new products has lagged behind. In many respects, Process Analytical Technology (PAT) is a new ‘omics’ for biopharmaceutical manufacture.
The biopharmaceuticals industry has undergone a number of revolutions in the past decade, not least the variety of ‘omics’ that focus on high throughput technologies to identify new product targets and can rapidly characterise those targets at small scale. However, it has been widely recognised that the technology used in the manufacturing of these in new products has lagged behind. In many respects, Process Analytical Technology (PAT) is a new ‘omics’ for biopharmaceutical manufacture.
The biopharmaceuticals industry has undergone a number of revolutions in the past decade, not least the variety of ‘omics’ that focus on high throughput technologies to identify new product targets and can rapidly characterise those targets at small scale. However, it has been widely recognised that the technology used in the manufacturing of these in new products has lagged behind. In many respects, Process Analytical Technology (PAT) is a new ‘omics’ for biopharmaceutical manufacture.
The FDA has recognised that imposed regulatory burdens had resulted in industry being slow to accept and implement new technology that would have improved processes by reducing process and product variability, cost and the patient risks associated with the variability. The suggestions put forward by the FDA provides a framework that puts together disparate subject areas under the one aim, to mitigate risk by applying sound science and engineering principles over the life cycle of pharmaceutical development (FDA panel).
The use of the component ‘PAT Tools’ are not new and the ‘PAT Carrots’ represent perceived drivers that will push PAT implementation forward (Figure 1). Apart from identifying the need to implement new technologies in the production environment, the FDA recognises the need to carry out PAT supporting activities throughout the development lifecycle. These supporting activities build up a ‘knowledge base’ around the product that forms the basis for process understanding. Although the advantages of process analytical tools in manufacturing are clearly laid out in the FDA guidance, much of the emphasis to date has been on implementing PAT within existing licensed commercial processes.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
The idea of a design space is a central concept to the new PAT regime and much has been accomplished to define a common understanding of what design space means (see draft ICH Q8 definition in box)
The concept of design space entails establishing a multivariate knowledge space that links critical process variables with critical to quality variables (CQA). This design space can be most efficiently mapped out using a variety of Design of Experiment (DoE) techniques, which minimise the number of experiments required. The description of design space suggests a single space in which a process operates. However, the DoE based design space is two spaces, (Factor and Response spaces) mapped onto each other by way of a mathematical transformation. A number of issues should be considered prior to planning a design space DoE:
1. Unit Operations
Many processes are a series of linked unit operations that progress raw materials through intermediate to final product in a batch wise manner. Some unit operations would be expected to have larger effects than others on the critical quality attributes. Formal risk assessment using Failure Mode Effect Analysis (FMEA) and other risk analysis tools allow users to rate each unit operation for their relative effect on quality (response) variables. Process capability indices on critical quality attributes (CQA) can be used as a useful metric to measure current state and improvements derived from PAT implementation.
2. Factor (Variable) and response selection
Variables that define the factor space need to be selected objectively. Formal risk assessment using Failure Mode Effect Analysis (FMEA) and other risk analysis tools allow users to rate variables for their effect on quality (response) variables. The assessment can be based on existing process knowledge. The assessment can also be aided with multivariate analysis (MVA) of historical process data and DoE variable screening designs.
3. Real time data
Although some process dynamics can be captured using DoE, DoE is unsuitable for analysis of real time data. Multivariate analysis tools such as PCA and Batch-PLS are more suited to this role. When DoE is used in conjunction with DoE, this powerful combination allows the user to identify critical process variables and model their relationship with CQAs including real time process dynamics effects.
PAT integration into process development
What is yet to be addressed are practical strategies to construct a process design space that spans the lifecycle of the product. Biopharmaceutical manufacturing processes usually consist of a set of unit operations connected in series, processing raw materials through intermediates to final product in a batch-wise manner. Each unit operation is described by a number of measured variables that are either controlled or free to vary. Only some of these variables will be critical to final product quality. This batch mode of processing means that each unit operation is run independently from the preceding or following operations. The complexity of many processes and the number of processing steps means that initial analysis should be focused on single unit operations. With infinite resource, it may be possible to investigate the design space for all unit operations. In practice, it makes sense to focus on the unit operations that are understood to contribute to most of the product quality variability.
The approach that many biopharmaceutical development organisations use to bring a candidate to the clinic and commercial licence has a number of features that aid building a design space over the course of the product development lifecycle. Biopharmaceutical development organisations rely on a platform technology approach where successive products in the pipeline are ‘plugged into’ a ‘skeleton’ manufacturing process. For monoclonal antibodies, this process is illustrated in Figure 1.
Some variation in the unit operation sequence between manufacturers will occur, but the skeleton process is used to speed product to proof of concept studies of first time in human studies and enable high product throughput through the development cycle. High throughput process development is achieved, in part, by using a limited set of ‘generic’ host cell lines, expression vectors, growth and production media and buffers that are progressed through this skeleton process. In conjunction with common scale up and downstream processing equipment, forming an existing skeleton process, an initial assessment of unit operation and process variability can be determined. This would add to the knowledge gained from previous product.
A Meta – DoE analogy for building a design space over a product development lifecycle
For the purposes of this paper, the upstream cell culture scale up and production stages will be used as an example. The cell culture steps are regarded2,3 to be key unit operations which affect CQA variability (Table 1). The mapping of a design space for a given product can be thought of in terms of a ‘meta’ DOE design through the process development lifecycle. At each Phase, (Figure 3, Figure 4, Figure 5 and Figure 6) combined use of DOE and Multivariate analysis captures process set-points, process dynamics of critical to quality (CtQ) process variables and their effect on CQA variability.
Stage 1: Early development (Figure 3)
A number of development steps shown in Figure 2 can provide data to form the basis of the design space. After cell line selection and process optimisation, multiple small scale batches are run to evaluate cell culture process robustness and reproducibility. Scale up and production batches’ use of manufacture material for toxicological studies and clinical trials provides additional data to assess reproducibility at a larger scale. These data acquired from early development defines the initial centre-points in the overall design space (Figure 3). At this stage there is little variation in the process factors and multivariate data analysis can be used to assess real time data to identify process variables that correlate with CQA variability. In conjunction with FMEA risk analysis and prior process knowledge, a panel of potential (CtQ) process variables can be identified.
Stage 2: Mid-term development (Figure 4)
Following first time in human studies (FTIH), further development of the process would involve expanding out the process space to a 3-level factorial space. The process variables identified as potential CtQ process variables in the preceding phases are used as factors in the design. The aim at this stage is to create a ‘granular’ normal operating range (NOR) and validate the variables as critical to quality variables. The real time data collected during this stage can be used to augment the multivariate models built during stage 1.
Stage 3: Late term development (Figure 5)
Stage 3 studies would further expand this space to extend the design space to a 5 level factorial space. The aim at this stage is to refine the detail within the design space and start to identify potential process failure regions. Again, the dynamics of the process are captured using multivariate analysis.
Stage 4: Late term development (Figure 6)
Stage 4 studies involve further expansion of the design space to increase the fine detail and push the design space into process failure. The aim is to refine understanding of where the limits of the design space are.
Summary
The strategy described above is intended to be applied to products where a skeleton process is already in place. Application of the strategy over multiple products will lead to enhanced understanding of key variables that affect product quality. As yet, a number of issues need to be reviewed within this strategy. Data acquisition and structured storage is critical to passing between each stage. In a case where a cell line change is required, there is little published data to compare the effect of a different cell line, derived from the same host cell bank on multivariate process trajectories. Similarly, there is little published work on multivariate techniques for process scale up and comparability for biopharmaceutical processes.
References
Gottschalk U (2005), BioPharm International 18(6) : pp42
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.